Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Degludec for Recurrent DKA
NCT03001323Terminated
- Sponsor
- Hennepin Healthcare Research Institute
- Start
- Jan 2017
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of insulin degludec in diabetes mellitus (DM) (2 arms), sponsored by Hennepin Healthcare Research Institute. Primary endpoint: Rate of recurrent Diabetic Ketoacidosis at 12 months. Started Jan 2017; status: terminated.
02
Drugs
insulin degludec
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03001323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001323.